HIV Infection: Immunology and Vaccine Design

该方案申请旨在利用世界领先的澳大利亚研究人员小组的技能，将新的艾滋病毒疫苗设计带入临床试验，改进疫苗设计并为商业化创造新的机会。首席研究员David Cooper教授、Peter Doherty教授（诺贝尔奖得主）、Stephen Kent教授和Ian Ramshaw教授取得了重大的科学发展，包括：创新的合作临床试验，T细胞免疫学的前沿研究，南半球唯一一个pc3水平的非人灵长类动物设施的建立，dna -病毒载体初级增强疫苗方案的T细胞免疫原性以及细胞因子共表达病毒载体疫苗的突破性研究。主要研究人员在艾滋病毒和T细胞生物学以及新型疫苗接种技术方面也取得了重大成就。这一小组之间的成功合作有着悠久的历史，从而获得了NIH的主要资助。

This program application seeks to draw on the skills of a world leading group of Australian researchers to bring novel HIV vaccine designs to clinical trials, improve vaccine design and create new opportunities for commercialisation. The Chief Investigators, Prof David Cooper, Prof Peter Doherty (Nobel Prize winner), A-Prof Stephen Kent and Prof Ian Ramshaw, have achieved major scientific developments including: innovative collaborative clinical trials, cutting edge research in T cell immunology, the establishment of the only PC3-level nonhuman primate facility in the Southern hemisphere, T cell immunogenicity of the DNA-viral vector prime-boost vaccine regimens and ground-breaking research on cytokine co-expressing viral vector vaccines. The Principle Investigators also have a record of substantial achievement in relation to HIV and T cell biology as well as novel vaccination technologies. There is a strong history of successful collaboration among this group leading to the award of major NIH funding.